257 related articles for article (PubMed ID: 30971393)
1. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
2. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride.
Antoniou T; Macdonald EM; Yao Z; Gomes T; Tadrous M; Ho JM; Mamdani MM; Juurlink DN;
BMC Musculoskelet Disord; 2018 May; 19(1):160. PubMed ID: 29789004
[TBL] [Abstract][Full Text] [Related]
6. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
7. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
[TBL] [Abstract][Full Text] [Related]
8. The Cardiovascular Safety of Dutasteride.
Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
[TBL] [Abstract][Full Text] [Related]
9. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
10. Association of Suicidality and Depression With 5α-Reductase Inhibitors.
Welk B; McArthur E; Ordon M; Anderson KK; Hayward J; Dixon S
JAMA Intern Med; 2017 May; 177(5):683-691. PubMed ID: 28319231
[TBL] [Abstract][Full Text] [Related]
11. Association between
Madersbacher S; Rieken M; Reuber K; Kostev K
Postgrad Med; 2023 Mar; 135(2):149-154. PubMed ID: 36408978
[TBL] [Abstract][Full Text] [Related]
12. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
[TBL] [Abstract][Full Text] [Related]
15. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
[TBL] [Abstract][Full Text] [Related]
16. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
17. Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
Yamanishi T; Asakura H; Seki N; Tokunaga S
Urol Int; 2021; 105(9-10):817-825. PubMed ID: 33690238
[TBL] [Abstract][Full Text] [Related]
18. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
19. Lack of Association between 5α-Reductase Inhibitors and Depression.
Dyson TE; Cantrell MA; Lund BC
J Urol; 2020 Oct; 204(4):793-798. PubMed ID: 32294395
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience.
Guevara-Cuellar CA; Parody-Rúa E; Garcia-Perdomo HA; Arenas-Duque A
Value Health Reg Issues; 2018 Dec; 17():174-182. PubMed ID: 30415110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
